AN ANALYSIS AND SIGNIFICANCE OF IMMUNOHISTOCHEMISTRY ER, PR AND HER2 TESTING FOR BREAST MALIGNANCY IN A TERTIARY CARE CENTER

<p><strong>Background</strong>: A significant development in the Breast malignancy, the expression of Hormone receptors in the tumor cells for the management and prognosis.</p>\n\n<p><strong>Aim of Study : </strong>This study was<strong> </strong>conducted to correlate Immunohistochemical expression of markers such as estrogen receptor( ER) , progesterone receptor (PR ),and Her-2/neu with clinical mainly age, sex and Histopathological parameters .</p>\n\n<p><strong>Materials and Methods</strong>: This prospective study was done at the tertiary care hospital from January 2019 to January 2020. 296 cases of Breast malignancy were studied. Immunohistochemistry (IHC) for ER, PR, and Her-2/neu was performed. The laboratory reporting was done according to the standard scoring system from CAP protocol 2019.</p>\n\n<p><strong>Results:</strong> According to the molecular basis of Breast tumor, the ER positive and Her-2 Negative was observed in 24.6% ( 73/296) cases , ER Positive and Her-2/neu Positive in 22.9 % ( 68/296) cases, whereas ER negative and Her-2 /neu positive in 21.6 % ( 64/296) cases. Triple marker (ER , PR and Her-2) negative cases were seen in 23.9 % ( 71/296). Triple marker positive cases were 6.75 % ( 20/296).</p>\n\n<p><strong>Conclusion</strong>: IHC markers studies in Breast malignancy is still gold standard for treating the patients and prognostic aspect.</p>